Prognostic Significance of Bone Metastases and Bisphosphonate Therapy in Patients with Renal Cell Carcinoma
- 1 September 2014
- journal article
- Published by Elsevier in European Urology
- Vol. 66 (3) , 502-509
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted TherapyEuropean Urology, 2014
- Combination of Zoledronic Acid and Targeted Therapy Is Active But May Induce Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell CarcinomaJournal of Oral and Maxillofacial Surgery, 2013
- Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastasesBritish Journal of Cancer, 2012
- Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumabNature Reviews Drug Discovery, 2012
- Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinomaEuropean Journal of Cancer, 2012
- Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancersJournal of Medical Economics, 2011
- Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastasesAnnals of Oncology, 2011
- Distribution of metastatic sites in renal cell carcinoma: a population-based analysisAnnals of Oncology, 2011
- Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999–2006Breast Cancer Research and Treatment, 2011
- Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006Prostate Cancer and Prostatic Diseases, 2011